Shutao Guo

Shutao Guo

Auto-generated profile, based on publicly available information

Shutao Guo

Nankai University

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2010 in ACS Nano
Verified
Journal Article
Closed access
SGShutao Guo
Shutao Guo
YHYuanyu Huang
Yuanyu Huang
QJQiao Jiang
Qiao Jiang
YSYun Sun
Yun Sun
LDLiandong Deng
Liandong Deng
XLXingjie Liang
Xingjie Liang

22 March 2021 in ACS Nano
Verified
Journal Article
Closed access
YZYinan Zhao
Yinan Zhao
TZTianyi Zhao
Tianyi Zhao
YCYingnan Cao
Yingnan Cao
JSJiao Sun
Jiao Sun
QZQuan Zhou
Quan Zhou
SZShubiao Zhang
Shubiao Zhang

1 November 2013 in Journal of Controlled Release
Verified
Journal Article
Closed access
ZXZhenghong Xu
Zhenghong Xu
SRSrinivas Ramishetti
Srinivas Ramishetti
YTYu-Cheng Tseng
Yu-Cheng Tseng
SGShutao Guo
Shutao Guo
YWYuhua Wang
Yuhua Wang
Leaf HuangLeaf Huang
Leaf Huang

1 October 2013 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
YWYuhua Wang
Yuhua Wang
ZXZhenghong Xu
Zhenghong Xu
SGShutao Guo
Shutao Guo
LZLu Zhang
Lu Zhang
ASArati Sharma
Arati Sharma
LHLeaf Huang
Leaf Huang
CD47 is a “self marker” that is usually overexpressed on the surface of cancer cells to enable them to escape immunosurveillance. Recognition of CD47 by its receptor, signal regulatory protein α (SIRPα), which is expressed in the macrophages, inhibits phagocytic destruction of cancer cells by the macrophages. In this study, we have first shown that clinical isolates of human melanoma significantly upregulate CD47, possibly as a mechanism to defend themselves against the macrophages. We then exploited RNA interference (RNAi) technology to test the hypothesis that knocking down CD47 in the tumor cells will render them targets for macrophage destruction; hence, creating a novel anti-cancer therapy. Anti-CD47 siRNA was encapsulated in a liposome-protamine-hyaluronic acid (LPH) nanoparticle (NP) formulation to address the challenge of targeted delivery of siRNA-based therapeutics in vivo. Efficient silencing of CD47 in tumor tissues with systemic administration of LPH(CD47) also significantly inhibited the growth of melanoma tumors. In a lung metastasis model, LPH(CD47) efficiently inhibited lung metastasis to about 27% of the untreated control. Moreover, no hematopoietic toxicity was observed in the animals that received multiple doses of LPH(CD47). Our findings indicate CD47 as a potential prognostic marker for melanoma development as well as a target for therapeutic intervention with RNAi-based nanomedicines.

22 August 2014 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
LMLei Miao
Lei Miao
SGShutao Guo
Shutao Guo
JZJing Zhang
Jing Zhang
WKWilliam Y. Kim
William Y. Kim
Leaf HuangLeaf Huang
Leaf Huang

1 June 2017 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
LMLei Miao
Lei Miao
SGShutao Guo
Shutao Guo
CLC. Michael Lin
C. Michael Lin
QLQi Liu
Qi Liu
Leaf HuangLeaf Huang
Leaf Huang